C. Molta

1.7k total citations
36 papers, 1.3k citations indexed

About

C. Molta is a scholar working on Rheumatology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, C. Molta has authored 36 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Rheumatology, 18 papers in Immunology and 12 papers in Pathology and Forensic Medicine. Recurrent topics in C. Molta's work include Systemic Lupus Erythematosus Research (21 papers), Psoriasis: Treatment and Pathogenesis (10 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). C. Molta is often cited by papers focused on Systemic Lupus Erythematosus Research (21 papers), Psoriasis: Treatment and Pathogenesis (10 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). C. Molta collaborates with scholars based in United States, United Kingdom and France. C. Molta's co-authors include Hong Kan, Deborah Robertson, Ronald Pedersen, B Freundlich, Robert Boggs, Gary Milligan, Enno Christophers, C.E.M. Griffiths, E. Daudén and Wolfram Sterry and has published in prestigious journals such as Journal of the American College of Cardiology, PEDIATRICS and Annals of the Rheumatic Diseases.

In The Last Decade

C. Molta

33 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Molta United States	20	916	888	268	232	221	36	1.3k
Grace S. Park United States	19	860 0.9×	409 0.5×	221 0.8×	114 0.5×	106 0.5×	31	1.4k
Hubert van Hoogstraten United States	18	917 1.0×	429 0.5×	516 1.9×	91 0.4×	93 0.4×	60	1.4k
Beverley Harrison United Kingdom	20	1.5k 1.6×	397 0.4×	479 1.8×	92 0.4×	191 0.9×	29	1.9k
Siegfried Wassenberg Germany	21	1.8k 2.0×	716 0.8×	726 2.7×	68 0.3×	102 0.5×	61	2.2k
Arijit Ganguli United States	22	439 0.5×	360 0.4×	191 0.7×	227 1.0×	49 0.2×	90	1.4k
Anders Gülfe Sweden	13	829 0.9×	387 0.4×	283 1.1×	37 0.2×	63 0.3×	21	1.1k
Molla Huq Australia	18	641 0.7×	429 0.5×	48 0.2×	78 0.3×	222 1.0×	42	1.2k
Sofia Ernestam Sweden	22	1.2k 1.3×	326 0.4×	452 1.7×	20 0.1×	145 0.7×	44	1.6k
Piet LCM van Riel Netherlands	15	557 0.6×	180 0.2×	152 0.6×	84 0.4×	30 0.1×	17	969
Carolyn Neville Canada	20	961 1.0×	362 0.4×	311 1.2×	15 0.1×	104 0.5×	40	1.3k

Countries citing papers authored by C. Molta

Since Specialization

Citations

This map shows the geographic impact of C. Molta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Molta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Molta more than expected).

Fields of papers citing papers by C. Molta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Molta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Molta. The network helps show where C. Molta may publish in the future.

Co-authorship network of co-authors of C. Molta

This figure shows the co-authorship network connecting the top 25 collaborators of C. Molta. A scholar is included among the top collaborators of C. Molta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Molta. C. Molta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kan, Hong, Peter Schulam, Suchi Saria, et al.. (2018). Factors associated with physicians’ prescriptions for rheumatoid arthritis drugs not filled by patients. Arthritis Research & Therapy. 20(1). 79–79. 11 indexed citations

Collins, Christopher, Maria Dall’Era, H. Kan, et al.. (2016). Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Science & Medicine. 3(1). e000118–e000118. 91 indexed citations

Kan, Hong, Saurabh Nagar, Jeetvan Patel, et al.. (2016). Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus. Clinical Therapeutics. 38(3). 610–624. 29 indexed citations

Lévy, Micheline, et al.. (2015). Antiphospholipid Antibodies in Patients with Childhood Onset Systemic Lupus erythematosus and Their Relatives. Contributions to nephrology. 99. 26–34.

Bruce, Ian N, Murray B. Urowitz, Ronald van Vollenhoven, et al.. (2015). OP0186 5-Year Organ Damage Accrual and Safety in Patients with Sle Treated with Belimumab Plus Standard of Care. Annals of the Rheumatic Diseases. 74. 142–142. 1 indexed citations

Askanase, Anca, Jinoos Yazdany, & C. Molta. (2014). Post-marketing Experiences with Belimumab in the Treatment of SLE Patients. Rheumatic Disease Clinics of North America. 40(3). 507–517. 20 indexed citations

Kan, Hong, Annie Guérin, Andrew P. Yu, et al.. (2013). A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus. Journal of Medical Economics. 16(6). 793–800. 12 indexed citations

Shah, Manan, et al.. (2013). Cumulative Burden of Oral Corticosteroid Adverse Effects and the Economic Implications of Corticosteroid Use in Patients With Systemic Lupus Erythematosus. Clinical Therapeutics. 35(4). 486–497. 61 indexed citations

Kan, H., et al.. (2013). THU0261 Outcomes in Systemic Lupus Erythematous (SLE) Patients with High Disease Activity Treated with Belimumab: Results from an Observational Study in the United States (U.S.). Annals of the Rheumatic Diseases. 72. A253–A254. 1 indexed citations

10.

Drenkard, Cristina, Gaobin Bao, Greg Dennis, et al.. (2013). Burden of Systemic Lupus Erythematosus on Employment and Work Productivity: Data From a Large Cohort in the Southeastern United States. Arthritis Care & Research. 66(6). 878–887. 76 indexed citations

11.

Christophers, Enno, Siegfried Segaert, Gary Milligan, C. Molta, & Robert Boggs. (2012). Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. Journal of Dermatological Treatment. 24(3). 193–198. 34 indexed citations

12.

Strohal, Robert, L. Puig, Edgardo Chouela, et al.. (2012). The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). Journal of Dermatological Treatment. 24(3). 169–178. 58 indexed citations

13.

FitzGerald, Oliver, Philip Helliwell, Philip J. Mease, et al.. (2011). Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. Annals of the Rheumatic Diseases. 71(3). 358–362. 51 indexed citations

14.

Gniadecki, Robert, Deborah Robertson, C. Molta, et al.. (2011). Self‐reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. Journal of the European Academy of Dermatology and Venereology. 26(11). 1436–1443. 59 indexed citations

15.

Sterry, Wolfram, J P Ortonne, Bruce Kirkham, et al.. (2010). Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 340(feb02 2). c147–c147. 186 indexed citations

16.

Landells, Ian, Amy S. Paller, David M. Pariser, et al.. (2010). Efficacy and safety of etanercept in children and adolescents aged≥8 years with severe plaque psoriasis. European Journal of Dermatology. 20(3). 323–328. 18 indexed citations

17.

Ortonne, J.‐P., Alain Taı̈eb, Anthony D. Ormerod, et al.. (2009). Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. British Journal of Dermatology. 161(5). 1190–1195. 53 indexed citations

18.

Ortonne, Jean‐Paul, C.E.M. Griffiths, E. Daudén, et al.. (2008). Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Expert Review of Dermatology. 3(6). 657–665. 44 indexed citations

19.

Raymond, Russell, Conrad Simpfendorfer, Anita Zeiler Arnold, et al.. (1991). Coronary angioplasty in the elderly patient: Short and longterm results. Journal of the American College of Cardiology. 17(2). A64–A64. 1 indexed citations

20.

Khan, Muhammad Anwar, Frederick Wolfe, Sue M. Kleinheksel, & C. Molta. (1987). HLA DR4 and B27 Antigens in Familial and Sporadic Rheumatoid Arthritis. Scandinavian Journal of Rheumatology. 16(6). 433–436. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact